KẾT QUẢ ĐIỀU TRỊ HÓA XẠ TRỊ ĐỒNG THỜI UNG THƯ THỰC QUẢN GIAI ĐOẠN TIẾN TRIỂN TẠI CHỖ TẠI VÙNG

Abstract

Objective: Evaluating the treatment results of  concurrent chemoradiotherapy for locoregionally advanced esophageal cancer and analyzing some related factors. Subject and method: cross-sectional, retrospective, longitudinal follow-up, no control on 61 patients who were diagnosed with squamous cell carcinoma esophagus, regardless of age and gender; treated with concurrent chemoradiotherapy using 3D radiotherapy technique with Paclitaxel-carboplatin regimen in weekly cycles at Military Hospital 103 from January 2019 to November 2022. Result: The mean age was 56.8 (32-75), 100.0% was male. Preoperative radiotherapy with a radiation dose of 41.4Gy and 5 cycles of chemotherapy accounted for 65.6%; 34.4% of patients received radical radiotherapy with a radiation dose of 50.4Gy and 6 cycles of chemotherapy). Patients had clinical respone  after treatment accounted for 80.3%. Symptoms of dysphagia were significantly reduced after treatment (p < 0.001). The response rate was 81.9%, with the highest rate of partial response patients (55.7%) according to RECIST 1.1 criteria. The progression rate during chemotherapy and radiotherapy was low (3.3%). The regimen was safe, with only mild complications, and dermatitis had the highest rate (67.0%). Analysis showed that better patient status, earlier disease stage according to T, N, and TNM were predictive factors for better response after treatment (p < 0.05). Conclusion: Concurrent preoperative and radical chemoradiotherapy is effective and well tolerated. This is a suitable treatment method for patients with esophageal cancer without distant metastasis.